Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LSH001
MIFTS: 71

Leishmaniasis

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leishmaniasis

About this section

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 76 53 55 43 3 44 15 73
Post-Kala-Azar Dermal Leishmaniasis 12 73
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 73
Cutaneous Leishmaniasis 53
Leishmaniasis, Visceral 73
Visceral Leishmaniasis 53
Kala-Azar 53

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Leishmaniasis

About this section
MedlinePlus : 43 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to visceral leishmaniasis and cutaneous leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Leishmaniasis is RN7SL1 (RNA, 7SL, Cytoplasmic 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Amphotericin B and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and liver, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

NIH Rare Diseases : 53 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 76 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Sources

Related Diseases for Leishmaniasis

About this section

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 visceral leishmaniasis 34.4 IFNG IL10 IL4 NOS2 SLC11A1 TLR2
2 cutaneous leishmaniasis 34.2 IFNG IL10 IL4 IL5 MPI SLC11A1
3 trypanosomiasis 31.0 IFNG IL10 IL1B IL4 TLR2 TNF
4 chagas disease 30.9 IFNG IL10 IL1B NOS2 TLR2 TLR4
5 human immunodeficiency virus infectious disease 30.8 IFNG IL10 TNF
6 anterior uveitis 30.8 TLR2 TLR4 TNF
7 leptospirosis 30.7 IFNG IL10 IL1B TLR2 TNF
8 arthritis 30.7 HLA-DRB1 IFNG IL10 IL1A IL1B TNF
9 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.6 IFNG IL10 IL4
10 acquired immunodeficiency syndrome 30.5 IFNG IL10 IL1B RN7SL1 TNF
11 malaria 30.4 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
12 leprosy 3 30.4 HLA-DRB1 IFNG IL10 IL4 SLC11A1 TLR2
13 lepromatous leprosy 30.4 IFNG IFNGR1 IL10 TLR2 TNF
14 psoriatic arthritis 30.3 HLA-DRB1 IL1A IL1B TNF
15 viral infectious disease 30.3 IFNG IL10 IL1B IL4 TNF
16 pulmonary tuberculosis 30.3 HLA-DRB1 IFNG IFNGR1 IL10 IL4 SLC11A1
17 rheumatoid arthritis 30.2 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1A IL1B
18 filariasis 30.2 IFNG IL10 IL5 TLR2 TLR4 TNF
19 filarial elephantiasis 30.2 IL10 IL4 IL5 TLR2
20 schistosomiasis 30.2 IFNG IFNGR1 IL10 IL4 IL5 TNF
21 sezary's disease 30.1 IFNG IL4 IL5
22 melioidosis 30.1 IFNG IL10 TLR2 TLR4 TNF
23 uveitis 30.1 IFNG IL10 IL1A IL4 TNF
24 systemic lupus erythematosus 30.1 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1B IL4
25 panuveitis 30.0 HLA-DRB1 IL10 TNF
26 bacterial infectious disease 30.0 IFNG IL10 IL1B ITGAM SLC11A1 TLR2
27 pericarditis 30.0 IFNG IL1B TNF
28 prostatitis 30.0 IL10 IL1B TNF
29 keratitis, hereditary 30.0 IL1B TLR2 TLR4
30 connective tissue disease 30.0 HLA-DQA1 HLA-DRB1 IFNG IL10 IL1A TNF
31 orofacial granulomatosis 29.9 IFNG IL10 IL4 TNF
32 diabetes mellitus 29.9 HLA-DQA1 HLA-DRB1 IFNG IL1A IL1B TNF
33 coccidiosis 29.9 IFNG IL10 IL4 TNF
34 hemorrhagic fever 29.9 HLA-DRB1 IFNG IL10 TNF
35 bacterial sepsis 29.9 IL10 NOS2 TLR4 TNF
36 mixed connective tissue disease 29.9 HLA-DRB1 IFNG IL10 TNF
37 toxoplasmosis 29.9 HLA-DQA1 IFNG IL10 IL1B IL4 TLR2
38 paracoccidioidomycosis 29.9 IFNG IL10 IL4 IL5 TLR2 TLR4
39 aphthous stomatitis 29.9 IL10 IL1B IL4 TLR2 TNF
40 meningitis 29.8 IFNG IL10 IL1B TLR2 TNF
41 rheumatic disease 29.8 HLA-DRB1 IFNG IL10 IL1B TNF
42 onchocerciasis 29.8 IL4 IL5 MPI
43 tonsillitis 29.8 IFNG IL1A IL1B IL4 TNF
44 multiple sclerosis 29.8 HLA-DRB1 IFNG IL10 IL1B IL4 IL5
45 lymphadenitis 29.7 IFNG IFNGR1 IL10 IL1B SLC11A1 TLR4
46 fascioliasis 29.7 IFNG IL10 IL1B
47 psoriasis 29.7 IFNG IL10 IL1A IL1B IL4 TNF
48 common variable immunodeficiency 29.7 IFNG IL10 IL4 IL5 TLR2 TNF
49 pneumonia 29.7 IL10 IL1B IL5 TLR2 TLR4 TNF
50 periodontitis 29.7 IFNG IL10 IL1A IL1B IL4 TLR2

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis
Sources

Symptoms & Phenotypes for Leishmaniasis

About this section

Human phenotypes related to Leishmaniasis:

32 (show all 24)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 32 hallmark (90%) HP:0001744
2 hepatomegaly 32 hallmark (90%) HP:0002240
3 fatigue 32 occasional (7.5%) HP:0012378
4 arthralgia 32 frequent (33%) HP:0002829
5 anemia 32 frequent (33%) HP:0001903
6 pancytopenia 32 hallmark (90%) HP:0001876
7 pallor 32 frequent (33%) HP:0000980
8 abnormal bleeding 32 hallmark (90%) HP:0001892
9 weight loss 32 frequent (33%) HP:0001824
10 thrombocytopenia 32 occasional (7.5%) HP:0001873
11 skin ulcer 32 hallmark (90%) HP:0200042
12 anorexia 32 occasional (7.5%) HP:0002039
13 papule 32 hallmark (90%) HP:0200034
14 lymphadenopathy 32 hallmark (90%) HP:0002716
15 increased antibody level in blood 32 frequent (33%) HP:0010702
16 leukopenia 32 occasional (7.5%) HP:0001882
17 skin plaque 32 hallmark (90%) HP:0200035
18 hypoalbuminemia 32 frequent (33%) HP:0003073
19 episodic fever 32 hallmark (90%) HP:0001954
20 rhinitis 32 hallmark (90%) HP:0012384
21 night sweats 32 hallmark (90%) HP:0030166
22 elevated hepatic transaminase 32 frequent (33%) HP:0002910
23 abnormal oral mucosa morphology 32 hallmark (90%) HP:0011830
24 abnormal macrophage morphology 32 hallmark (90%) HP:0004311

UMLS symptoms related to Leishmaniasis:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Leishmaniasis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 HLA-DQA1 IFNG IFNGR1 IL10 IL1A IL1B
2 immune system MP:0005387 10.25 HLA-DQA1 IFNG IFNGR1 IL10 IL1A IL1B
3 homeostasis/metabolism MP:0005376 10.21 IFNG IFNGR1 IL10 IL1A IL1B IL4
4 cardiovascular system MP:0005385 10.19 IFNG IFNGR1 IL10 IL1A IL1B MPI
5 digestive/alimentary MP:0005381 10.18 IFNG IFNGR1 IL10 IL4 IL5 NOS2
6 integument MP:0010771 10.07 IFNG IFNGR1 IL10 IL1A IL1B IL4
7 neoplasm MP:0002006 10 IFNG IFNGR1 IL10 IL1A IL1B IL5
8 liver/biliary system MP:0005370 9.97 IFNG IFNGR1 IL10 IL4 IL5 NOS2
9 nervous system MP:0003631 9.9 IFNG IFNGR1 IL10 IL1B IL4 ITGAM
10 respiratory system MP:0005388 9.56 IFNG IL10 IL4 IL5 NOS2 TLR2
11 skeleton MP:0005390 9.32 IFNG IFNGR1 IL10 IL1B IL4 MPI
Sources

Drugs & Therapeutics for Leishmaniasis

About this section

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 5280965 14956
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 1263-89-4, 7542-37-2 165580
6
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
7
Primaquine Approved Phase 4 90-34-6 4908
8
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
9
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
10
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Meglumine antimoniate Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 133-51-7
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
14 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Analgesics Phase 4,Phase 2,Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
24 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
25 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
28 Antiviral Agents Phase 4,Phase 3,Not Applicable
29 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
30 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
32 Anesthetics Phase 4
33 Chloroquine diphosphate Phase 4 50-63-5
34 Antimalarials Phase 4
35 Nucleic Acid Synthesis Inhibitors Phase 4
36 HIV Protease Inhibitors Phase 4,Phase 3
37 Anti-HIV Agents Phase 4,Phase 3
38 Cytochrome P-450 CYP3A Inducers Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
40 Atazanavir Sulfate Phase 4
41 Reverse Transcriptase Inhibitors Phase 4
42 Anti-Retroviral Agents Phase 4,Phase 3
43 Cytochrome P-450 CYP3A Inhibitors Phase 4
44
protease inhibitors Phase 4,Phase 3
45 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
46
Pentamidine Approved, Investigational Phase 3,Phase 2 100-33-4 4735
47
Ethanol Approved Phase 2, Phase 3 64-17-5 702
48
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
49
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
50
Pentoxifylline Approved, Investigational Phase 2, Phase 3,Phase 3 6493-05-6 4740

Interventional clinical trials:

(show top 50) (show all 155)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
3 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
5 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
6 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
7 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
8 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
9 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
10 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
11 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
12 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
13 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
14 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Unknown status NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
15 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
16 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
17 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
18 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
19 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
20 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
21 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
22 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
23 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
24 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
25 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
26 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
27 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
28 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
29 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
30 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
31 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
32 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
33 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
34 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
35 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
36 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
37 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
38 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
39 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
40 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
41 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
42 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3 Calcipotriol plus Nicotinamide;Calcipotriol
43 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
44 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
45 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
46 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
47 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
48 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate
49 Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis Terminated NCT00682656 Phase 2, Phase 3 Glucantime®;Zithromax ®
50 Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Terminated NCT00317629 Phase 3 controlled nitric oxide releasing patch;meglumine antimoniate

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: leishmaniasis

Sources

Genetic Tests for Leishmaniasis

About this section
Sources

Anatomical Context for Leishmaniasis

About this section

MalaCards organs/tissues related to Leishmaniasis:

41
Skin, Testes, Liver, Spleen, Bone, T Cells, Bone Marrow
Sources

Publications for Leishmaniasis

About this section

Articles related to Leishmaniasis:

(show top 50) (show all 4236)
# Title Authors Year
1
Gene expression profile of cytokines produced in biopsies from patients with American cutaneous leishmaniasis. ( 30273562 )
2019
2
Zoonotic Leishmaniasis, Bosnia and Herzegovina. ( 30511917 )
2019
3
Meteorological conditions, elevation and land cover as predictors for the distribution analysis of visceral leishmaniasis in Sinkiang province, Mainland China. ( 30235597 )
2019
4
DNA prime-protein boost vaccine encoding HLA-A2, HLA-A24 and HLA-DR1 restricted epitopes of CaNA2 against visceral leishmaniasis. ( 30285279 )
2019
5
FcI^-RI, FcI^-RII and IL-10 as predictive biomarkers for post-therapeutic cicatrization time in monocytes from cutaneous leishmaniasis patients. ( 29908029 )
2018
6
Andrographolide engineered gold nanoparticle to overcome drug resistant visceral leishmaniasis. ( 29421940 )
2018
7
Fulminant presentation of oral mucosal leishmaniasis as severe stomatitis and periodontitis. ( 29380732 )
2018
8
Cryotherapy of cutaneous leishmaniasis caused by <i>Leishmania major</i> in BALB/c mice: A comparative experimental study. ( 29916447 )
2018
9
Exploring sand fly salivary proteins to design multi-epitope subunit vaccine to fight against visceral leishmaniasis. ( 29377223 )
2018
10
Visceral leishmaniasis presenting with pancytopenia and circulating blastlike lymphocytes. ( 29930152 )
2018
11
Brain Parenchyma (pons) Involvement by Visceral Leishmaniasis: A Case Report. ( 29963097 )
2018
12
An international qualitative study exploring patients' experiences of cutaneous leishmaniasis: study set-up and protocol. ( 29909372 )
2018
13
Sensitivity and specificity of an in-clinic point-of-care PCR test for the diagnosis of canine leishmaniasis. ( 29428091 )
2018
14
Treatment of cutaneous leishmaniasis with thermotherapy in Brazil: an efficacy and safety study. ( 29924242 )
2018
15
NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis. ( 29867949 )
2018
16
Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. ( 29415078 )
2018
17
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. ( 29860672 )
2018
18
Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis. ( 29448040 )
2018
19
Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. ( 29953494 )
2018
20
Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia. ( 29375842 )
2018
21
Extensive Post-Kala-Azar Dermal Leishmaniasis. ( 29441312 )
2018
22
Potential application of rLc36 protein for diagnosis of canine visceral leishmaniasis. ( 29412359 )
2018
23
Recent progress in drug targets and inhibitors towards combating leishmaniasis. ( 29452111 )
2018
24
Environmental factors associated with canine visceral leishmaniasis in an area with recent introduction of the disease in the State of Rio de Janeiro, Brazil. ( 29412315 )
2018
25
Leishmaniasis treatment: update of possibilities for drug repurposing. ( 28930585 )
2018
26
Canine Visceral Leishmaniasis; A Seroepidemiological Survey in Jiroft District, Southern Kerman Province, Southeastern Iran in 2015. ( 29963087 )
2018
27
Diagnostic lipid changes in patients with visceral leishmaniasis. ( 29848097 )
2018
28
Development of Thiophene Compounds as Potent Chemotherapies for the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania major</i>. ( 29973498 )
2018
29
Positive Influence of Behavior Change Communication on Knowledge, Attitudes, and Practices for Visceral Leishmaniasis/Kala-azar in India. ( 29386327 )
2018
30
High frequency of subclinical Leishmania infection among HIV-infected patients living in the endemic areas of visceral leishmaniasis in Fars province, southern Iran. ( 29860572 )
2018
31
Epidemiological aspects of human and canine visceral leishmaniasis in State of Alagoas, Northeast, Brazil. ( 29412243 )
2018
32
Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP). ( 29444079 )
2018
33
Correction: B Cell: T Cell Interactions Occur within Hepatic Granulomas during Experimental Visceral Leishmaniasis. ( 29894507 )
2018
34
Arnica Tincture Cures Cutaneous Leishmaniasis in Golden Hamsters. ( 29329207 )
2018
35
Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia. ( 29378537 )
2018
36
Efficacy of Four <i>Solanum</i> spp. Extracts in an Animal Model of Cutaneous Leishmaniasis. ( 29874837 )
2018
37
Visceral leishmaniasis in an infant gorilla (Gorilla gorilla gorilla): Clinical signs, diagnosis, and successful treatment with single-dose liposomal amphotericin B. ( 29956831 )
2018
38
Molecular detection of Leishmania (Leishmania) infantum in phlebotomine sandflies from a visceral leishmaniasis endemic area in northwestern of SALo Paulo State, Brazil. ( 29373820 )
2018
39
First case report of atypical disseminated cutaneous leishmaniasis in an opium abuser in Iran. ( 29451599 )
2018
40
Cutaneous Leishmaniasis in the Metropolitan City of Multan, Pakistan, a Neglected Tropical Disease. ( 29415246 )
2018
41
Climate and environmental factors affecting the incidence of cutaneous leishmaniasis in Isfahan, Iran. ( 29427273 )
2018
42
The genetically determined production of the alarmin eosinophil-derived neurotoxin is reduced in visceral leishmaniasis. ( 29193305 )
2018
43
Dermoscopy of Post Kala-Azar Dermal Leishmaniasis. ( 29441313 )
2018
44
Rare Tongue Compromising of Mucocutaneous Leishmaniasis by Leishmania Subgenus Viannia. ( 29519666 )
2018
45
Health economic evaluation of moist wound care in chronic cutaneous leishmaniasis ulcers in Afghanistan. ( 29444705 )
2018
46
Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis. ( 29744736 )
2018
47
The ubiquitous parasite: leishmaniasis in an elderly man. ( 29963511 )
2018
48
First detection of Leishmania DNA in Psammomys obesus and Psammomys vexillaris: Their potential involvement in the epidemiology of leishmaniasis in Tunisia. ( 29413886 )
2018
49
Molecular detection of Leishmania infantum DNA and host blood meal identification in Phlebotomus in a hypoendemic focus of human leishmaniasis in northern Algeria. ( 29958283 )
2018
50
Liposomal Elongation Factor-1I+ Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis. ( 29441060 )
2018
Sources

Variations for Leishmaniasis

About this section
Sources

Expression for Leishmaniasis

About this section
Search GEO for disease gene expression data for Leishmaniasis.
Sources

Pathways for Leishmaniasis

About this section

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.13 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
2
PEDF Induced Signaling 64
Show member pathways
 13.76 IFNG IFNGR1 IL10 IL1A IL1B IL4
3
TGF-Beta Pathway 64
Show member pathways
 13.62 IFNG IFNGR1 IL10 IL1A IL1B IL4
4
Akt Signaling 64
Show member pathways
 13.52 IL10 IL1A IL1B IL4 IL5 ITGAM
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.48 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
6
IL-2 Pathway 64
Show member pathways
 13.33 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL1A IL1B
7
Toll-like Receptor Signaling Pathway 37 1
Show member pathways
 13.15 IFNG IFNGR1 IL10 IL1B NOS2 TLR2
8
Allograft rejection 1 37
Show member pathways
 13.01 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
9
Influenza A 37
Show member pathways
 12.9 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL1A IL1B
10
Pathways in cancer 37
12.88 IFNG IFNGR1 IL4 IL5 NOS2
11
Immune response NFAT in immune response 22
Show member pathways
 12.78 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL4
12
NF-KappaB Family Pathway 64
Show member pathways
 12.76 IL1A IL1B TLR2 TLR4 TNF
13
4-1BB Pathway 64
Show member pathways
 12.74 IFNG IFNGR1 IL1A IL1B TNF
14
NF-kappaB Signaling 4
12.7 IFNG IL10 IL1B IL4 TLR2 TNF
15
TRAF Pathway 64
Show member pathways
 12.68 IL1A IL1B TLR2 TLR4 TNF
16
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 IFNG IL10 IL1B NOS2 TNF
17
T cell receptor signaling pathway 37
Show member pathways
 12.59 IFNG IL10 IL1A IL1B IL4 IL5
18
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.49 IFNG IFNGR1 IL10 IL4 IL5
19
IL-17 Family Signaling Pathways 65
Show member pathways
 12.49 IFNG IL1B IL4 IL5 TLR2 TNF
20
Toll Comparative Pathway 64
Show member pathways
 12.47 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
21
Th17 cell differentiation 37
Show member pathways
 12.47 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
22
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.42 IFNG IL10 IL1A IL1B IL4 IL5
23
Selenium Micronutrient Network 1
Show member pathways
 12.39 IFNG IL1B IL4 TNF
24
Necroptosis 37
Show member pathways
 12.37 IFNG IFNGR1 IL1A IL1B TLR4 TNF
25
IL-1 Family Signaling Pathways 65
Show member pathways
 12.36 IL1A IL1B NOS2 TLR2 TNF
26
Epstein-Barr virus infection 37
12.35 HLA-DQA1 HLA-DRB1 TLR2 TNF
27
Colorectal Cancer Metastasis 64
12.35 IFNG IFNGR1 NOS2 TLR2 TLR4 TNF
28
Toxoplasmosis 37
Show member pathways
 12.34 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
29
Diseases associated with the TLR signaling cascade 66
Show member pathways
 12.32 IL1A TLR2 TLR4 TNF
30
Bacterial infections in CF airways 22
Show member pathways
 12.31 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
31
Phagosome 37
12.28 HLA-DQA1 HLA-DRB1 ITGAM TLR2 TLR4
32
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.25 IL10 IL1A IL1B TNF
33
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.23 IFNG IFNGR1 IL10 IL1A IL1B IL4
34
Th1 Differentiation Pathway 65
Show member pathways
 12.23 IFNG IFNGR1 IL10 IL1B TLR2 TLR4
35
Osteoclast differentiation 37
12.2 IFNG IFNGR1 IL1A IL1B TNF
36
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 12.2 IFNG IL1B IL4 ITGAM TLR2 TLR4
37
MAPK Pathway 72
Show member pathways
 12.19 IL1A IL1B IL5 TLR2 TLR4
38
Fluid shear stress and atherosclerosis 37
12.18 IFNG IL1A IL1B TNF
39
Spinal Cord Injury 1
12.17 IFNG IL1A IL1B IL4 NOS2 TLR4
40
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
12.16 IFNG IL10 IL4 IL5 ITGAM TNF
41
IL12-mediated signaling events 1
Show member pathways
 12.14 HLA-DRB1 IFNG IL1B IL4 NOS2
42
Interleukin-4 and 13 signaling 66
12.14 IL10 IL1A IL1B IL4 ITGAM NOS2
43
HIF-1 signaling pathway 37
12.02 IFNG IFNGR1 NOS2 TLR4
44
Salmonella infection (KEGG) 37
12.02 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
45
Hematopoietic cell lineage 37
11.99 HLA-DQA1 HLA-DRB1 IL1A IL1B IL4 IL5
46
Tuberculosis 37
11.99 HLA-DQA1 HLA-DRB1 IFNG IFNGR1 IL10 IL1A
47
Amoebiasis 37
11.95 IFNG IL10 IL1B ITGAM NOS2 TLR2
48
Dendritic Cells Developmental Lineage Pathway 65
11.92 IFNG IL10 IL1B ITGAM TNF
49
Innate Lymphoid Cell Differentiation Pathways 65
11.92 IFNG IL10 IL1B IL4 IL5 ITGAM
50
NF-kappa B signaling pathway 37
11.91 IL1B TLR4 TNF
Sources

GO Terms for Leishmaniasis

About this section

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 IFNG IL10 IL1A IL1B IL4 IL5
2 endosome membrane GO:0010008 8.92 HLA-DQA1 HLA-DRB1 SLC11A1 TLR4

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B TLR2 TLR4 TNF
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL5 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.95 IL10 IL1B NOS2 TLR4 TNF
4 defense response to Gram-negative bacterium GO:0050829 9.9 NOS2 SLC11A1 TLR4
5 positive regulation of JNK cascade GO:0046330 9.89 IL1B TLR4 TNF
6 positive regulation of inflammatory response GO:0050729 9.89 TLR2 TLR4 TNF
7 response to glucocorticoid GO:0051384 9.88 IL10 IL1B TNF
8 interferon-gamma-mediated signaling pathway GO:0060333 9.88 HLA-DQA1 HLA-DRB1 IFNG IFNGR1
9 regulation of insulin secretion GO:0050796 9.87 IFNG IL1B NOS2 TNF
10 positive regulation of gene expression GO:0010628 9.86 IFNG IL1A IL1B IL4 SLC11A1 TLR2
11 response to lipopolysaccharide GO:0032496 9.85 IL10 IL1B NOS2 SLC11A1 TLR2 TLR4
12 positive regulation of B cell proliferation GO:0030890 9.84 IL4 IL5 TLR4
13 positive regulation of phagocytosis GO:0050766 9.84 IL1B SLC11A1 TNF
14 positive regulation of interleukin-6 production GO:0032755 9.84 IL1B TLR2 TLR4 TNF
15 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 IL1A IL1B TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 IL1B TLR2 TLR4 TNF
17 negative regulation of interferon-gamma production GO:0032689 9.82 HLA-DRB1 IL10 TLR4
18 negative regulation of interleukin-6 production GO:0032715 9.81 IL10 TLR4 TNF
19 positive regulation of cytokine secretion GO:0050715 9.81 IL10 IL1A TNF
20 positive regulation of interferon-gamma production GO:0032729 9.81 IL1B SLC11A1 TLR4 TNF
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 IFNG IL1B TLR4 TNF
22 positive regulation of interleukin-12 production GO:0032735 9.78 IFNG TLR2 TLR4
23 positive regulation of chemokine production GO:0032722 9.77 TLR2 TLR4 TNF
24 microglial cell activation GO:0001774 9.77 ITGAM TLR2 TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 IFNG IL1B TNF
26 inflammatory response GO:0006954 9.76 IL10 IL1A IL1B IL5 SLC11A1 TLR2
27 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.73 IL1A IL1B
28 regulation of cytokine secretion GO:0050707 9.73 TLR2 TLR4
29 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNG IFNGR1
30 I-kappaB phosphorylation GO:0007252 9.73 TLR2 TLR4
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL10 IL1B TNF
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 IL1B TLR2 TLR4 TNF
33 negative regulation of interleukin-17 production GO:0032700 9.72 IFNG TLR4
34 positive regulation of podosome assembly GO:0071803 9.72 IL5 TNF
35 response to molecule of bacterial origin GO:0002237 9.72 IL10 TLR2
36 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
37 cellular response to lipoteichoic acid GO:0071223 9.71 TLR2 TLR4
38 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
39 T-helper 1 type immune response GO:0042088 9.71 HLA-DRB1 TLR4
40 positive regulation of interleukin-8 production GO:0032757 9.71 IL1B TLR2 TLR4 TNF
41 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
42 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
43 ectopic germ cell programmed cell death GO:0035234 9.7 IL1A IL1B
44 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF
45 negative regulation of cytokine secretion involved in immune response GO:0002740 9.69 IL10 TNF
46 positive regulation of neuroinflammatory response GO:0150078 9.69 IL1B TNF
47 positive regulation of fever generation GO:0031622 9.69 IL1B TNF
48 chronic inflammatory response to antigenic stimulus GO:0002439 9.68 IL1B TNF
49 positive regulation of killing of cells of other organism GO:0051712 9.68 IFNG NOS2
50 regulation of isotype switching GO:0045191 9.68 IL10 IL4

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 IFNG IL10 IL1A IL1B IL4 IL5
2 MHC class II receptor activity GO:0032395 9.16 HLA-DQA1 HLA-DRB1
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4
Sources

Sources for Leishmaniasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....